TR201815668T4 - Obezite tedavisine yönelik bileşikler ve bunların kullanım metotları. - Google Patents

Obezite tedavisine yönelik bileşikler ve bunların kullanım metotları. Download PDF

Info

Publication number
TR201815668T4
TR201815668T4 TR2018/15668T TR201815668T TR201815668T4 TR 201815668 T4 TR201815668 T4 TR 201815668T4 TR 2018/15668 T TR2018/15668 T TR 2018/15668T TR 201815668 T TR201815668 T TR 201815668T TR 201815668 T4 TR201815668 T4 TR 201815668T4
Authority
TR
Turkey
Prior art keywords
celastrol
obese
leptin
mice
formulation
Prior art date
Application number
TR2018/15668T
Other languages
English (en)
Turkish (tr)
Inventor
Ozcan Umut
Majzoub Joseph
Mazitschek Ralph
Cakir Isin
Cabi Serkan
Original Assignee
Childrens Medical Ct Corp
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201815668(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Ct Corp, Massachusetts Gen Hospital filed Critical Childrens Medical Ct Corp
Publication of TR201815668T4 publication Critical patent/TR201815668T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TR2018/15668T 2012-09-27 2013-09-26 Obezite tedavisine yönelik bileşikler ve bunların kullanım metotları. TR201815668T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27

Publications (1)

Publication Number Publication Date
TR201815668T4 true TR201815668T4 (tr) 2018-11-21

Family

ID=49304418

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/15668T TR201815668T4 (tr) 2012-09-27 2013-09-26 Obezite tedavisine yönelik bileşikler ve bunların kullanım metotları.

Country Status (21)

Country Link
US (6) US9968575B2 (2)
EP (3) EP3434268B1 (2)
JP (2) JP6480864B2 (2)
CN (3) CN111529534A (2)
AU (3) AU2013323528B2 (2)
BR (1) BR112015006848A2 (2)
CA (2) CA3030272C (2)
CY (1) CY1121166T1 (2)
DK (1) DK2900230T3 (2)
ES (1) ES2696626T3 (2)
HR (1) HRP20181879T1 (2)
HU (1) HUE040496T2 (2)
LT (1) LT2900230T (2)
PL (1) PL2900230T3 (2)
PT (1) PT2900230T (2)
RS (1) RS58010B1 (2)
RU (2) RU2768868C2 (2)
SI (1) SI2900230T1 (2)
SM (1) SMT201800604T1 (2)
TR (1) TR201815668T4 (2)
WO (1) WO2014052583A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
CA3044998A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
US20250134923A1 (en) * 2021-09-09 2025-05-01 Junion Labs Pte. Ltd. Superabsorbent hydrogels with lipase inhibitor
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
HUP9802609A2 (hu) 1995-06-30 1999-03-29 Eli Lilly And Co. A diabetes kezelésére szolgáló eljárás
ATE259650T1 (de) 1995-08-17 2004-03-15 Amgen Inc Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
PT866720E (pt) 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
CA2263826A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
WO1998012224A1 (en) 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
CA2275183A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
ATE223229T1 (de) 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
WO1998055139A1 (en) 1997-06-06 1998-12-10 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
JP4199421B2 (ja) 1998-08-10 2008-12-17 アムジエン・インコーポレーテツド デキストラン−レプチン結合体、医薬組成物および関連方法
AU6396999A (en) 1998-10-02 2000-04-26 Amgen, Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU781460B2 (en) 1999-02-12 2005-05-26 Amgen, Inc. Glycosylated leptin compositions and related methods
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
AU2003286549B2 (en) 2002-10-21 2006-11-30 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
EP1715539B1 (en) 2004-01-16 2012-11-07 Mitsubishi Materials Corporation Separator for fuel cell, method of producing separator, and solid oxide fuel cell
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
CA2613041C (en) 2005-09-30 2012-03-06 Morinaga Milk Industry Co., Ltd. Agent for improving insulin resistance
EP1948191B1 (en) 2005-11-01 2013-01-16 The Regents of the University of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (en) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
EP2152252A4 (en) * 2006-11-13 2010-06-02 Univ Columbia SELECTIVE PROTEASOMIC INHIBITORS FOR THE TREATMENT OF DIABETES
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
UA97707C2 (ru) * 2007-11-14 2012-03-12 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
EP2271213A4 (en) * 2008-02-01 2011-06-29 Scripps Research Inst METHOD FOR THE TREATMENT OF A GRADE SUFFERED BY PROTEIN HOMEOSTASIS
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
JP5780549B2 (ja) 2009-04-17 2015-09-16 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
CA2808359C (en) 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
EP2617726A4 (en) * 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
JP6478908B2 (ja) 2012-05-25 2019-03-06 バーグ エルエルシー 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
US11045439B2 (en) 2021-06-29
CA2886393C (en) 2019-02-26
ES2696626T3 (es) 2019-01-17
US9968575B2 (en) 2018-05-15
CA2886393A1 (en) 2014-04-03
EP3434268B1 (en) 2022-04-20
SI2900230T1 (sl) 2019-01-31
EP2900230B1 (en) 2018-08-15
DK2900230T3 (en) 2018-11-12
US20250161252A1 (en) 2025-05-22
CY1121166T1 (el) 2020-05-29
HRP20181879T1 (hr) 2019-02-08
AU2016247206B2 (en) 2018-08-02
CN104822374A (zh) 2015-08-05
CN111529535A (zh) 2020-08-14
US20210008019A1 (en) 2021-01-14
US20170304245A1 (en) 2017-10-26
AU2013323528B2 (en) 2016-11-10
JP6480864B2 (ja) 2019-03-13
AU2018256619A1 (en) 2018-11-22
CN111529534A (zh) 2020-08-14
RU2650646C2 (ru) 2018-04-16
PT2900230T (pt) 2018-11-26
JP6743211B2 (ja) 2020-08-19
AU2016247206A1 (en) 2016-11-10
EP4082541A1 (en) 2022-11-02
US12064408B2 (en) 2024-08-20
RU2018112067A (ru) 2019-03-07
JP2019070052A (ja) 2019-05-09
RU2768868C2 (ru) 2022-03-25
LT2900230T (lt) 2019-01-10
CA3030272C (en) 2021-09-28
RU2018112067A3 (2) 2021-06-24
US20180185314A1 (en) 2018-07-05
RU2015115696A (ru) 2016-11-20
AU2018256619B2 (en) 2020-07-23
PL2900230T3 (pl) 2019-02-28
HK1213190A1 (en) 2016-06-30
HUE040496T2 (hu) 2019-03-28
JP2015531376A (ja) 2015-11-02
AU2013323528A1 (en) 2015-04-09
BR112015006848A2 (en) 2018-05-22
US20150250753A1 (en) 2015-09-10
EP3434268A1 (en) 2019-01-30
RS58010B1 (sr) 2019-02-28
EP2900230A1 (en) 2015-08-05
US10653654B2 (en) 2020-05-19
US20210275482A1 (en) 2021-09-09
WO2014052583A1 (en) 2014-04-03
SMT201800604T1 (it) 2019-01-11
US9925161B2 (en) 2018-03-27
CA3030272A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
DK2900230T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
US20050181047A1 (en) Compositions and methods for timed release of water-soluble nutritional supplements
MX2008009647A (es) Cisteamina recubierta entéricamente, cistamina y derivados de ella.
AU2015235979A1 (en) Celastrol and derivatives for the treatment of obesity
US20140112983A1 (en) Nitrite compositions and uses thereof
US20050181044A1 (en) Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
AU2008318270A1 (en) Improved tablet coating
KR101745750B1 (ko) 경구 투여가능한 상피세포 성장 인자의 약학적 펠릿
DK3074033T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
US20110027357A1 (en) Compositions and methods for timed release of water-soluble nutritional supplements
CN102716135B (zh) 羽扇豆酮在制备预防或治疗糖尿病的产品中的应用
US20210154161A1 (en) Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
WO2002049636A1 (en) An antidiabetic composition of amino acids
HK1213190B (en) Compounds for the treatment of obesity and methods of use thereof
CN115884764A (zh) 用于治疗乙型冠状病毒感染的半胱胺前体化合物
HK40083451A (en) Compounds for the treatment of obesity and methods of use thereof